Latest Developments in the Treatment of Anal Cancer

Video

This video reviews the standard of care for locally advanced anal carcinoma, examines new trials studying novel agents and immunotherapy in the advanced setting, and highlights the need for HPV vaccination for preventing the disease.

In this video, Cathy Eng, MD, of the University of Texas MD Anderson Cancer Center, reviews the standard of care for locally advanced anal carcinoma, including options for chemotherapy, which is used concurrently with radiation therapy, and surgery for patients with bulky tumors and for those who aren’t cured with chemoradiotherapy.

In the metastatic setting, investigational trials are studying novel agents and immunotherapy-a recently published phase II trial found that 24% of treatment-refractory patients responded to nivolumab. These ongoing studies could change the way patients with advanced disease are treated.

Eng also highlights the need for human papillomavirus (HPV) vaccination for the prevention of this disease as well as other HPV-related cancers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content